Savara Inc. (SVRA)

Market Cap	1.47B +196.8%
Revenue (ttm)	n/a
Net Income	-118.84M
EPS	-0.53
Shares Out	253.52M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,719,075
Open	5.79
Previous Close	5.64
Day's Range	5.67 - 5.89
52-Week Range	1.89 - 7.01
Beta	0.31
Analysts	Buy
Price Target	7.33 (+26.82%)
Earnings Date	May 12, 2026

About SVRA

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 70
• Stock Exchange: NASDAQ
• Ticker Symbol: SVRA
• Website: https://www.savarapharma.com

Analyst Summary

According to 9 analysts, the average rating for SVRA stock is "Buy." The 12-month stock price target is $7.33, which is an increase of 26.82% from the latest price.

Price Target

$7.33

(26.82% upside)

Analyst Consensus: Buy